Press Releases Race Oncology Limited

Equities

Market Closed - Australian S.E. Other stock markets 02:10:36 2024-05-15 EDT			5-day change	1st Jan Change
1.61 ^AUD	-2.42%		+27.78%	+91.67%

03-26	Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	MT
03-18	Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	CI

Race Oncology's breakthrough in cancer cell treatment	05-15	AQ
Race Oncology looks to accelerate clinical development of bisantrene	02-28	AQ
Race Oncology appoints Dr Daniel Tillett as CEO	11-23	AQ
Race Oncology highlights impressive bisantrene clinical data	11-07	AQ
Race Oncology kicks off safety studies for RC220	23-10-09	AQ
Race Oncology at the heart of cancer care	23-08-09	AQ
Race Oncology announces deal with manufacturer Ardena to develop companyÃ¢€™s new IV formulation RC220	23-07-19	AQ
Race Oncology poised for observational heart protection breast cancer trial	23-03-14	AQ
Race Oncology tabs drug industry veteran Damian Clarke-Bruce as companyÃ¢€™s new Managing Director/CEO	22-12-15	AQ
Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO	22-12-15	EQ
Race Oncology welcomes positive pre-IND meeting for Zantrene	22-11-24	AQ
Race Oncology welcomes positive pre-IND meeting for Zantrene	22-11-24	EQ
Race Oncology : Update - Notification of buy-back - RAC	22-07-27	PU
Race Oncology : RAC Quarterly Investor Presentation	22-07-27	PU
Race Oncology : Update - Notification of buy-back - RAC	22-07-25	PU
Race Oncology : Quarterly Activity Report & Appendix 4C	22-07-21	PU
Race Oncology : EMD AML MDS Trial Expands to Europe	22-06-07	PU
Race Oncology : Quarterly Activity Report & Appendix 4C	22-04-20	PU
Race Oncology : Zantrene highly effective in EMD AML Mouse Model	22-03-16	PU
Race Oncology : ASX Small and Mid-Cap Conference Presentation	22-03-14	PU

No results for this search